Literature DB >> 24415052

Anterior approach for Pancoast tumor resection.

Lorenzo Spaggiari1, Massimiliano D'Aiuto, Giulia Veronesi, Francesco Leo, Piergiorgio Solli, Maria Elena Leon, Roberto Gasparri, Domenico Galetta, Francesco Petrella, Alessandro Borri, Paolo Scanagatta.   

Abstract

Tumors arising anteriorly in the apex of the chest were long considered unresectable because of early invasion of vascular structures limiting radical resection through the conventional Paulson approach. These tumors became operable in 1993 when Dartevelle popularized the cervico-thoracic transclavicular technique for resecting these neoplasms. Since then several different surgical approaches to anterior Pancoast tumors have been proposed, drastically improving the rate of radical resections of these tumors. However, there is no consensus on which anterior surgical approach provides the best access to all of the apical non-small cell lung cancers of the thoracic inlet. Moreover, it is still unclear if integrated neoadjuvant and adjuvant treatments can improve the rates of complete resection, local recurrence and long-term survival.

Entities:  

Year:  2007        PMID: 24415052     DOI: 10.1510/mmcts.2005.001776

Source DB:  PubMed          Journal:  Multimed Man Cardiothorac Surg        ISSN: 1813-9175


  2 in total

1.  Utility and reproducibility of 3-dimensional printed models in pre-operative planning of complex thoracic tumors.

Authors:  Elizabeth George; Maria Barile; Anji Tang; Ory Wiesel; Antonio Coppolino; Andreas Giannopoulos; Steven Mentzer; Michael Jaklitsch; Andetta Hunsaker; Dimitrios Mitsouras
Journal:  J Surg Oncol       Date:  2017-09       Impact factor: 3.454

Review 2.  Superior sulcus (Pancoast) tumors: current evidence on diagnosis and radical treatment.

Authors:  Christophoros N Foroulis; Paul Zarogoulidis; Kaid Darwiche; Nikolaos Katsikogiannis; Nikolaos Machairiotis; Ilias Karapantzos; Kosmas Tsakiridis; Haidong Huang; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.